Test Search

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
08/04/2010
Benzene Toxicity

  more information
04/16/2010
Holiday Schedule for Patient Service Centers

  more information
04/14/2010
RML through JVHL is an Aetna Preferred Provider

  more information
09/18/2009
Ordering Tests for Seasonal Flu A/B and H1N1

  more information
06/10/2009
2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests.

  more information
04/10/2009
SERUM FREE LIGHT CHAINS, A New Test for Patients with Monoclonal Gammopathies

  more information
04/10/2009
UPDATE ON CRP AND hsCRP

  more information
02/04/2009
Article Answers Questions Re: Testing for GC/Chlamydia in Liquid Based Pap Collection Vials

  more information
10/10/2008
News & Notes Fall 2008

  more information
08/12/2008
Congratulations to Beth Peak

  more information
08/04/2008
RML, Inc. Receives Accreditation From College of American Pathologists

  more information
03/20/2008
Winter 2008 News & Notes

  more information
12/17/2007
Albuminuria signals increased cardiovascular risk

  more information
10/23/2007
New definition of "MI" poised for world domination

  more information
10/19/2007
News & Notes Summer 2007

  more information
05/18/2007
www.mybiopsy.org Informative Website Answers Questions About Cancer

  more information





02/26/2004
Abstract from JAMA, 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities
Karl F. Loomis, M.D.

2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities 
 
Thomas C. Wright, Jr, MD; J. Thomas Cox, MD; L. Stewart Massad, MD; Leo B. Twiggs, MD; Edward J. Wilkinson, MD; for the 2001 ASCCP-Sponsored Consensus Conference

Objective:  To provide evidence-based consensus guidelines for the management of women with cervical cytological abnormalities and cervical cancer precursors.

Participants:  A panel of 121 experts in the diagnosis and management of cervical cancer precursors, including representatives from 29 professional organizations, federal agencies, and national and international health organizations, were invited to participate in a consensus conference sponsored by the American Society for Colposcopy and Cervical Pathology (ASCCP).

Evidence and Consensus Process:  Guidelines for the management of women with cervical cytological abnormalities were developed through a multistep process. Starting 6 months before the conference, working groups developed draft management guidelines based on formal literature reviews of English-language articles published in 1988-2001, as well as input from the professional community at large, obtained using interactive Internet-based bulletin boards. On September 6-8, 2001, the ASCCP Consensus Conference was held in Bethesda, Md. Guidelines with supporting evidence were presented and underwent discussion, revision, and voting.

Conclusions:  Management of women with atypical squamous cells (ASC) depends on whether the Papanicolaou test is subcategorized as of undetermined significance (ASC-US) or as cannot exclude high-grade squamous intraepithelial lesion (HSIL) (ASC-H). Women with ASC-US should be managed using a program of 2 repeat cytology tests, immediate colposcopy, or DNA testing for high-risk types of human papillomavirus (HPV). Testing for HPV DNA is the preferred approach when liquid-based cytology is used for screening. In most instances, women with ASC-H, low-grade squamous intraepithelial lesion, HSIL, and atypical glandular cells should be referred for immediate colposcopic evaluation.

For the complete article click here.

JAMA. 2002;287:2120-2129